clinical trial · NCT06931405
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
Chronic Inducible UrticariaChronic Spontaneous UrticariaBLU-808Placebo
brief summary
This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).
started
May 28, 2025
primary completion
Dec 31, 2026
completion
Dec 31, 2026
last updated
Feb 17, 2026
official title
A Phase 2 Study to Evaluate the Safety, Tolerability, and Clinical Activity of BLU-808, a Wild Type KIT Inhibitor, in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol